tozinameran bnt162b2 comirnaty  (BioNTech)

Journal: eBioMedicine

Article Title: A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity

doi: 10.1016/j.ebiom.2025.105619

Figure Lengend Snippet: Differential efficacy of human plasma Abs elicited by SARS-CoV-2 vaccination or vaccination plus infection in protecting TKI mice against Delta infection . (a) Timelines of SARS-CoV-2 vaccination and infection for plasma donors. Plasma samples were collected on the indicated days from the three donor groups: 2-dose + inf Delta (n = 7; two doses of BNT162b2 vaccine followed by infection with Delta); 3-dose (n = 10; three doses of BNT162b2 vaccine); and 3-dose + inf Omicron (n = 5; three doses of BNT162b2 vaccine followed by infection with Omicron BA.1 or BA.2). Values in green represent the median ± interquartile range (IQR) days between the 2nd or 3rd vaccination and symptom onset; values in red represent the median ± IQR days between natural exposure or vaccination and plasma collection. Infection windows for 2-dose + inf Delta and 3-dose + inf Omicron groups were deduced from known symptom onset dates. (b) Anti-Delta spike (S) protein IgG ELISA, anti-Delta receptor-binding domain (RBD) IgG ELISA, pVSV-S Delta neutralisation assay, or PRNT Delta of plasma collected from donors in the 2-dose + inf Delta group or the 3-dose group. Data are presented as the geometric mean ± error from one experiment. White and red circles represent individual and pooled samples, respectively. (c) Experimental protocol for the data shown in (d). TKI mice were injected intraperitoneally with 500 μl of pooled plasma from the 2-dose + inf Delta or 3-dose groups or from SARS-CoV-2-naïve and unvaccinated donors (control). One day later, mice were inoculated intranasally with Delta (10 3 PFU), and nasal turbinate (nt), lungs, and blood samples were harvested on day 2 post-infection. (d) RT-qPCR analysis of Delta subgenomic (sg) RNA and plaque assay of infectious virus in the nt and/or lung tissues of TKI mice on day 2 post-infection. Circles represent individual mice and dotted lines indicate the limit of detection. Data are presented as the mean ± SEM of 8–10 mice/group, pooled from two independent experiments. Group means were compared by the Mann–Whitney test (b) or the unpaired Kruskal–Wallis and Dunn's multiple comparison tests (d). ∗ P < 0.05, ∗∗ P < 0.01.

Article Snippet: We investigated the ability of the TKI mice to support Delta, Omicron BA.2, and Omicron BA.5 infection and replication in the respiratory tract; evaluated the pharmacokinetics (PK) of a human anti-Omicron mAb and its efficacy in preventing SARS-CoV-2 infection; and compared the protective efficacy of plasma from three human cohorts who had been vaccinated twice with the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Comirnaty/tozinameran, BioNTech/Pfizer) and subsequently either received a third BNT162b2 vaccination or became infected with Delta or Omicron BA.1 or BA.2.

Techniques: Clinical Proteomics, Infection, Enzyme-linked Immunosorbent Assay, Binding Assay, Injection, Control, Quantitative RT-PCR, Plaque Assay, Virus, MANN-WHITNEY, Comparison